Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 85Stomach Neoplasms 16Esophageal Neoplasms 14Neoplasms 10Cholangiocarcinoma 10Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 9Neoplasm Metastasis 8Adenocarcinoma Of Esophagus 8Esophageal Squamous Cell Carcinoma 7Endometrial Neoplasms 7Colorectal Neoplasms 7Pancreatic Adenocarcinoma 6Ovarian Neoplasms 6Lung Neoplasms 6Gallbladder Neoplasms 6Carcinoma, Ovarian Epithelial 6Adenocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4Prostatic Neoplasms 4Melanoma 4Biliary Tract Neoplasms 4Urinary Bladder Neoplasms 3Sarcoma 3Liver Neoplasms 3Gastric Adenocarcinoma 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Anus Neoplasms 3Advanced Pancreatic Cancer 3

Interventions

Taxes 1Hydroxychloroquine 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Untreated Resectable Pancreatic Adenocarcinoma × Taxes × Gastrointestinal × Clear all
NCT04669197 2025-08-15

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer

HonorHealth Research Institute

Phase 2 Active not recruiting
19 enrolled
Gastrointestinal

Untreated Resectable Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡